Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The SYRE news page on Stock Titan aggregates company press releases, clinical updates, and capital markets announcements so readers can follow how Spyre’s programs and corporate activities evolve over time.
In its public communications, Spyre highlights a pipeline of investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, with programs such as SPY001, SPY002, SPY072, and SPY003. News items frequently cover interim Phase 1 data, such as reports that SPY003 was well tolerated and exhibited an approximately 85-day half-life, and that SPY002 and SPY072 showed pharmacokinetic profiles supporting potential quarterly or twice-yearly maintenance dosing. Updates also describe the design and enrollment status of the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
Investors and followers of SYRE can also find announcements about stock offerings, use of proceeds, and equity inducement awards granted under the company’s equity plans, as well as participation in scientific congresses and investor conferences. Together, these news items provide insight into Spyre’s clinical development progress, financing activities, and broader corporate strategy as disclosed by the company.
For users tracking SYRE, this page offers a centralized view of Spyre Therapeutics’ official news flow, including trial milestones, interim study findings, and key financing events drawn from press releases and related disclosures.
Spyre Therapeutics (NASDAQ: SYRE) has initiated dosing in its Phase 2 SKYWAY basket trial for SPY072, their pioneering anti-TL1A antibody targeting rheumatic diseases. The trial focuses on treating patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).
SPY072 is designed for superior potency and convenience, with potential for quarterly or twice-yearly subcutaneous maintenance dosing. The SKYWAY trial, alongside the SKYLINE study, is expected to provide 9 proof-of-concept readouts in 2026-27. The company targets commercial markets exceeding $60B in annual revenue, with topline data expected in 2026.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on developing antibody treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases, has announced its participation in two major healthcare investor conferences in June 2025.
The company will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 8:10am ET, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20am ET. Live webcasts and replays will be accessible through Spyre's investor relations website.
Spyre Therapeutics (NASDAQ: SYRE) presented promising data from its ongoing Phase 1 trial of SPY001, a novel half-life extended α4β7 antibody for Inflammatory Bowel Disease (IBD) treatment, at Digestive Disease Week 2025. The trial results showed SPY001 is well-tolerated with a half-life more than three times longer than vedolizumab. A single dose demonstrated rapid and sustained α4β7 receptor saturation at expected Phase 2 trough concentrations.
The company remains on schedule to launch its platform Phase 2 trial in mid-2025, testing SPY001 as both monotherapy and in combination with SPY002 (TL1A) and SPY003 (IL-23). Initial monotherapy data is expected in 2026. Preclinical data also showed that combined inhibition of α4β7 integrin and TL1A cytokine demonstrated superior results compared to monotherapy in mouse colitis models.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on antibody engineering for IBD and immune-mediated diseases treatment, has announced equity inducement awards. The company's Compensation Committee approved stock options to purchase 64,400 shares of common stock for seven non-executive employees under the 2018 Equity Inducement Plan.
The stock options come with a 10-year term and an exercise price of $14.66 per share, matching Spyre's closing price on May 1, 2025. The vesting schedule includes 25% after one year and the remaining vesting monthly over the following three years, subject to continued employment.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on antibody engineering for IBD and immune-mediated diseases treatment, has announced new equity inducement awards. The company's independent Compensation Committee approved stock options to purchase 93,200 shares for five non-executive employees under their 2018 Equity Inducement Plan.
The stock options were granted on April 1, 2025, with a 10-year term and an exercise price of $15.295 per share, matching Spyre's closing price on that date. The vesting schedule includes 25% after the first year of employment, followed by monthly vesting of 1/48th of the shares, contingent on continued service with the company.
Spyre Therapeutics (NASDAQ: SYRE) has initiated dosing in a Phase 1 clinical trial of SPY003, its half-life extended anti-IL-23 monoclonal antibody, marking their fourth on-time clinical trial initiation in nine months. The trial (NCT06873724) is a double-blind, placebo-controlled single-ascending dose study expected to enroll approximately 56 healthy adult volunteers.
Preclinical data shows SPY003 is highly potent with potential for quarterly or biannual dosing, suggesting improved efficacy and convenience over first-generation anti-IL-23 antibodies. The study's primary endpoint is safety, with pharmacokinetics as a secondary endpoint.
Interim pharmacokinetic and safety data are anticipated in the second half of 2025. Following interim results, Spyre plans to incorporate SPY003 into its Phase 2 platform trial in ulcerative colitis, which will evaluate three investigational monotherapies and three investigational combination therapies.